iifl-logo-icon 1
iifl-logo-icon 1
iifl-logo-icon 1
Home

Ajanta Pharma Ltd AGM

₹2,266.6
(2.11%)
Jul 5, 2024|03:39:05 PM

Ajanta Pharma CORPORATE ACTIONS

07/07/2023calendar-icon
06/07/2024calendar-icon
PurposeAGM DateAnnouncement Date
AGM18 Jul 202329 May 2023
Forty-Fourth (44th) Annual General Meeting (AGM) of the Company will be held on Tuesday, 18th July 2023 at 11.00 a.m. through Video-conference or Other Audio-Visual Means We hereby inform that the Forty-Fourth Annual General Meeting (AGM) of the Company will be held on Tuesday, 18th July 2023 at 11.00 a.m. through Video Conferencing or Other Audio-Visual Means. Pursuant to Regulation 34(1) of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the Annual Report and Business Responsibility & Sustainability Report of the Company for the financial year 2022-23 along with Notice of the AGM. The Annual report, Business Responsibility & Sustainability Report and the Notice of AGM are being sent through electronic mode to members whose e-mails ids are registered and the same are also uploaded on the Companys website www.ajantapharma.com/ajanta/Investors/annual_results/?year=2022-23. (As Per BSE Announcement Dated on 16.06.2023) Pursuant to Regulation 47 of the Listing Regulations, please find enclosed notice published in newspapers regarding e-voting information for the 44th Annual General Meeting of the Company in terms of Section 108 of the Companies Act, 2013 read with Rule 20 of Companies (Management and Administration) Rules, 2014 (as amended) and Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in the following newspapers on 17th June 2023: 1. Mumbai edition of Free Press Journal; 2. Mumbai edition of Navshakti. (As Per BSE Announcement Dated on 19.06.2023) Pursuant to Regulation 44 of LODR, we submit herewith the following: a. Details of voting results on each resolution set out in the notice and b. Consolidated Scrutinizers report dated 18th July 2023. (As per BSE Announcement Dated on 18/07/2023)

Ajanta Pharma: Related News

No record found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

QUICKLINKS FOR Ajanta Pharma Ltd

Information
Share PriceFutures PriceOption Chain
Financials
Profit & LossBalance SheetCash FlowKey Ratios
Results
Quarterly ResultHalf Yearly ResultNine Monthly ResultAnnual Result
News
Company
Marketplus
Derivativesplus
IPOplus
Mutual Fundsplus
Calculatorsplus
Nifty 50plus
Companyplus
Loansplus
Knowledge Centerplus
Newsplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Marketplus
Derivativesplus
IPOplus
Mutual Fundsplus
Calculatorsplus
Nifty 50plus
Companyplus
Loansplus
Knowledge Centerplus
Newsplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

About
IIFL Group
Products & Services
Trading Documentation
Useful Links
ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.